Prostate Cancer
Reports summarize prostate cancer research from Sidney Kimmel Center for Prostate and Urologic Cancers
Published in Cancer Weekly, June 1st, 2010
Research findings, 'Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer,' are discussed in a new report. According to a study from the United States, "An open-label, dose-escalating phase Ib/IIa trial was performed to establish a safety profile of ascending doses of cetuximab (IMC C225) in combination with doxorubicin administered weekly for 6 treatments in patients with metastatic castration-resistant prostate cancer. The secondary endpoint was to assess the efficacy of cetuximab in combination with doxorubicin as well as to determine the optimal biologic dose and the maximum tolerated...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-06-01)
More Articles from Cancer Weekly
- Prostate Cancer
Scientists find protein spurs spread of prostate cancer - Pancreatic Cancer
Researchers from University of Nebraska Medical Center detail new studies and findings in the area of pancreatic cancer - Colon Cancer
Data on colon cancer published by researchers at University of North Carolina, Department of Epidemiology - Prostate Cancer
Reports outline prostate cancer research from University of Washington, Department of Urology - Bowel Cancer
Investigators at University of Warwick release new data on bowel cancer - Prostate Cancer
Findings from University of Colorado in prostate cancer reported - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
